Sciety

PeptiSystems focuses on manufacturing and supplying instruments for the solid-phase synthesis of peptide and oligonucleotide therapeutics.

Capitainer AB, based in Stockholm, Sweden, specializes in manufacturing innovative blood collection devices for micro sampling, allowing patients to collect their own volume-defined dried blood spots at home. Founded in 2016, Capitainer's technology offers a more accurate and convenient alternative to traditional blood sampling methods, significantly reducing the need for patients to travel for tests. By facilitating remote blood sample collection that can be sent to laboratories through regular mail, Capitainer enhances the efficiency of healthcare providers and contributes to cost and environmental savings associated with managing conventional blood samples.

PharmNovo AB is a Swedish company that specializes in developing therapeutic drugs for neuro diseases, particularly focusing on chronic pain and hyper excitability disorders. Founded in 2008 and based in Lund, the company is dedicated to creating novel Delta Opioid Receptor Agonists (DORAs) that aim to provide safe and effective alternatives to traditional opioid medications, which have been associated with addiction and toxicity. By leveraging advancements in neuroscience and translational medicine, PharmNovo seeks to address the significant unmet medical need for chronic pain treatments that affect a substantial portion of the adult population in the United States and Europe. Their lead drug candidate, PN6047, is designed to reduce chronic pain and combat hypersensitivity, ultimately improving patients' quality of life through non-addictive therapeutic options.

NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.

Encare AB, founded in 2009 and headquartered in Stockholm, Sweden, specializes in web-based software solutions designed to enhance perioperative care through the implementation of Enhanced Recovery after Surgery (ERAS) protocols. The company provides an interactive platform that enables surgical clinics to collect, document, and analyze performance data, facilitating improved patient recovery times and overall health outcomes. Encare's software includes components such as an ERAS protocol system, an audit system for surgeries, and tools for comparing outcomes, all aimed at delivering evidence-based best practices in surgical care. With rights to commercialize protocols developed by the ERAS Society, Encare has successfully deployed its solutions in over 120 hospitals across multiple countries, including Canada, several European nations, and the United States, thereby contributing to significant improvements in efficiency and quality of care in surgical settings.

Capitainer AB, based in Stockholm, Sweden, specializes in manufacturing innovative blood collection devices for micro sampling, allowing patients to collect their own volume-defined dried blood spots at home. Founded in 2016, Capitainer's technology offers a more accurate and convenient alternative to traditional blood sampling methods, significantly reducing the need for patients to travel for tests. By facilitating remote blood sample collection that can be sent to laboratories through regular mail, Capitainer enhances the efficiency of healthcare providers and contributes to cost and environmental savings associated with managing conventional blood samples.

Akiram Therapeutics is a Swedish biotech company specializing in targeted radioimmunotherapy for cancer treatment. The company leverages a proprietary antibody that targets the cancer marker CD44v6, combined with a radiation component, to create therapies that have demonstrated strong preclinical results in models of cancers lacking effective treatments. Akiram Therapeutics aims to develop novel radioactive molecules and pharmaceuticals that enhance the visualization and treatment of aggressive solid tumors. Its research focuses on significant indications, including head and neck cancer, acute myeloid leukemia, lung cancer, and aggressive thyroid cancer. Headquartered in Uppsala, Sweden, the company is composed of experts in radiation science, cancer precision medicine, and drug development, dedicated to advancing innovative therapeutic solutions in oncology.

PharmNovo AB is a Swedish company that specializes in developing therapeutic drugs for neuro diseases, particularly focusing on chronic pain and hyper excitability disorders. Founded in 2008 and based in Lund, the company is dedicated to creating novel Delta Opioid Receptor Agonists (DORAs) that aim to provide safe and effective alternatives to traditional opioid medications, which have been associated with addiction and toxicity. By leveraging advancements in neuroscience and translational medicine, PharmNovo seeks to address the significant unmet medical need for chronic pain treatments that affect a substantial portion of the adult population in the United States and Europe. Their lead drug candidate, PN6047, is designed to reduce chronic pain and combat hypersensitivity, ultimately improving patients' quality of life through non-addictive therapeutic options.

Encare AB, founded in 2009 and headquartered in Stockholm, Sweden, specializes in web-based software solutions designed to enhance perioperative care through the implementation of Enhanced Recovery after Surgery (ERAS) protocols. The company provides an interactive platform that enables surgical clinics to collect, document, and analyze performance data, facilitating improved patient recovery times and overall health outcomes. Encare's software includes components such as an ERAS protocol system, an audit system for surgeries, and tools for comparing outcomes, all aimed at delivering evidence-based best practices in surgical care. With rights to commercialize protocols developed by the ERAS Society, Encare has successfully deployed its solutions in over 120 hospitals across multiple countries, including Canada, several European nations, and the United States, thereby contributing to significant improvements in efficiency and quality of care in surgical settings.

Capitainer AB, based in Stockholm, Sweden, specializes in manufacturing innovative blood collection devices for micro sampling, allowing patients to collect their own volume-defined dried blood spots at home. Founded in 2016, Capitainer's technology offers a more accurate and convenient alternative to traditional blood sampling methods, significantly reducing the need for patients to travel for tests. By facilitating remote blood sample collection that can be sent to laboratories through regular mail, Capitainer enhances the efficiency of healthcare providers and contributes to cost and environmental savings associated with managing conventional blood samples.

NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.

Synartro is a Swedish research and development company focused on creating innovative treatments for osteoarthritis (OA) by utilizing patented drug delivery technology in conjunction with established medications. Its lead program, SYN321, features a novel therapy that combines diclofenac, a nonsteroidal anti-inflammatory drug, with hyaluronan to enhance pain relief for knee OA, a condition that affects many patients inadequately. Synartro aims to improve treatment efficacy through local injection methods that ensure sustained drug release while minimizing systemic side effects, thereby enabling clinicians to potentially slow or halt disease progression. The company is positioned to expand its offerings beyond knee OA, addressing a significant unmet need in the management of osteoarthritis.

SAGA Diagnostics AB is a company specializing in molecular genetic tests and services aimed at enhancing cancer diagnostics and disease monitoring for healthcare providers, biopharmaceutical firms, and academic institutions. Founded in 2016 as a spin-out from a research group at Lund University, SAGA focuses on the analysis of circulating tumor DNA (ctDNA), a critical biomarker for cancer. The company offers a range of services, including gene mutation analysis, chromosome analysis, and non-invasive liquid biopsy testing, which allows for the ultrasensitive detection of actionable mutations. SAGA's proprietary technology supports oncologists and drug developers by enabling the stratification of patient groups and monitoring treatment responses, thereby facilitating more precise cancer medicine and improving patient outcomes. Based in Lund, Sweden, SAGA is driven by a team of experienced scientists and professionals dedicated to advancing cancer research and clinical diagnostics.

Capitainer AB, based in Stockholm, Sweden, specializes in manufacturing innovative blood collection devices for micro sampling, allowing patients to collect their own volume-defined dried blood spots at home. Founded in 2016, Capitainer's technology offers a more accurate and convenient alternative to traditional blood sampling methods, significantly reducing the need for patients to travel for tests. By facilitating remote blood sample collection that can be sent to laboratories through regular mail, Capitainer enhances the efficiency of healthcare providers and contributes to cost and environmental savings associated with managing conventional blood samples.

PharmNovo AB is a Swedish company that specializes in developing therapeutic drugs for neuro diseases, particularly focusing on chronic pain and hyper excitability disorders. Founded in 2008 and based in Lund, the company is dedicated to creating novel Delta Opioid Receptor Agonists (DORAs) that aim to provide safe and effective alternatives to traditional opioid medications, which have been associated with addiction and toxicity. By leveraging advancements in neuroscience and translational medicine, PharmNovo seeks to address the significant unmet medical need for chronic pain treatments that affect a substantial portion of the adult population in the United States and Europe. Their lead drug candidate, PN6047, is designed to reduce chronic pain and combat hypersensitivity, ultimately improving patients' quality of life through non-addictive therapeutic options.

Synartro is a Swedish research and development company focused on creating innovative treatments for osteoarthritis (OA) by utilizing patented drug delivery technology in conjunction with established medications. Its lead program, SYN321, features a novel therapy that combines diclofenac, a nonsteroidal anti-inflammatory drug, with hyaluronan to enhance pain relief for knee OA, a condition that affects many patients inadequately. Synartro aims to improve treatment efficacy through local injection methods that ensure sustained drug release while minimizing systemic side effects, thereby enabling clinicians to potentially slow or halt disease progression. The company is positioned to expand its offerings beyond knee OA, addressing a significant unmet need in the management of osteoarthritis.

Cavis Technologies is an innovative start-up company supplying invasive cardiology care units with a unique device for improved control and safety.

Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, specializing in the development of a metabolism-based liquid biopsy platform aimed at the early detection and monitoring of cancer. Founded in 2017, the company focuses on measuring biomarkers in blood and urine, employing machine learning and artificial intelligence algorithms to identify cancer signatures. Elypta is actively conducting the AURORAX clinical trial series to explore applications for its platform, particularly in renal cell carcinoma, while also investigating other cancer indications. The technology includes a new in vitro diagnostic laboratory assay kit, which enables comprehensive profiling of glycosaminoglycan metabolites and supports a range of applications from screening to treatment response monitoring, facilitating earlier interventions in cancer care.

Single Technologies AB is a Stockholm-based company founded in 2012 that specializes in advanced imaging technology for applications in research, drug discovery, and diagnostics. The company has developed a novel single-molecule-sensitive 3D sequencing system that allows for high-throughput and cost-effective DNA reading. This technology leverages a combination of single-molecule imaging, large-area confocal scanning, and nanotechnology to provide precise genomic data. By enabling accurate diagnostics and personalized treatments, Single Technologies aims to enhance the capabilities of the healthcare industry through its innovative solutions in genomics and sequencing.

Athera is a biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics for the prevention and treatment of cardiovascular disease (“CVD”). The Company initiated its current program in 2005, harnessing breakthrough innovations made at the world-renowned Karolinska Institutet, Solna, Sweden. The company currently has a proprietary clinical development stage program, PC-mAb, supported by an approved proprietary companion diagnostic kit.

Likvor has developed a unique instrument for measuring the cerebrospinal fluid (brain fluid) pressure and flow. Likvor AB is an Umeå based medical device company which has developed a system to be used in neurological investigations. Likvor CELDA System is the result of close to 40 years of research at Umeå University and Umeå University Hospital assessing cerebrospinal fluid (CSF) dynamics. Likvor AB is marketing Likvor CELDA System and CELDA Tools. Likvor AB was established in 2007. Likvor AB first product Likvor CELDA System, was available to the market in 2009 when it was CE-marked. The company is certified according to ISO-13485. Likvor AB continues to develop new methods and devices in the area of CSF dynamics, together with the researchers at Umeå University and Umeå University Hospital.

Lipigon Pharmaceuticals AB is a biopharmaceutical company based in Umeå, Sweden, that specializes in the development of therapeutics for dyslipidemia and metabolic diseases. Founded in 2010, the company focuses on innovative treatments targeting lipoprotein lipase (LPL), an enzyme crucial for fat metabolism. Lipigon aims to address conditions related to low LPL activity, such as elevated blood fats, insulin resistance, and metabolic syndrome. The company's portfolio includes treatments for rare diseases like lipodystrophy and homozygous familial hypercholesterolemia, where existing therapies are insufficient. Lipigon has entered into a collaboration with AstraZeneca to further develop LPL-based pharmaceuticals, potentially receiving significant financial support as milestones in development and sales are achieved.

Cartana AB is a biotechnology company based in Solna, Sweden, specializing in mapping gene expression in brain tissue through In Situ Sequencing (ISS). Founded in 2017, Cartana's innovative technology allows for the simultaneous analysis of hundreds of genes within individual cells while preserving tissue morphology. This capability is essential for advancing research and biomarker discovery, treatment validation, and the development of future diagnostic tools. The company's flagship product, NeuroKit: Brain Cell Mapping, can identify over 100 genes in a single tissue section. Cartana also provides sequencing services that include sample preparation and analysis, facilitating deeper understanding of brain functions and diseases as well as tumors and other organs. As of August 2020, Cartana operates as a subsidiary of 10x Genomics, Inc.

Empe Diagnostics is committed to combat drug resistance in Tuberculosis (TB) and Sexually Transmitted Disease (STD), EMPE Diagnostics aims to develop simple and rapid diagnostic solutions for infectious diseases with a special focus on antimicrobial resistance.

The idea for PictureMyLife born out of a personal experience and a need that They have seen are the others - to make life easier, more inspiring and stimulating for children with impaired comprehension skills as well as their families and educators. Today, much of the communication of children in handwritten contact books and schedules that put together the parts that must first be printed and then cut and pasted in place. They want to help change Their digital platform. They are founders and working with PictureMyLife named Yvonne Malmström Grimme, Lollo Andström, Lisa Lidgren and Maria Skantz and They have many years of experience in communication and education in health care, health and social care.

Medpro Clinic Group is a healthcare business that operates six innovative care centers and provides care with a personal service and high standards. Medpro Clinic's operations are run by a dedicated staff who are passionate about care with high quality and preserved integrity. Medpro Clinic Group is headquartered in Sweden.

Liv Diagnostics AB, founded in 2016 and based in Mölndal, Sweden, specializes in developing diagnostic tools that analyze tumor cells to assess the risk of metastasis. The company's innovative approach focuses on direct analysis of cancer cell behavior, contrasting with traditional indirect diagnostic methods. By mimicking the natural environment of cells within the human body, Liv Diagnostics enables physicians to directly observe the behavior of living cancer cells. Their product, CellRACE, quantifies the migration capacity of these cells, providing critical predictive information about metastasis risk. Liv Diagnostics operates as a subsidiary of Cline Scientific AB.

1928 Diagnostics is a digital health company that specializes in bioinformatics, focusing on the analysis of genomic data to combat antibiotic resistance. The company provides a cloud-based platform designed to assist microbiologists in utilizing their sequencing data effectively. Its software service facilitates outbreak tracing and diagnostics, enabling healthcare providers to implement comprehensive infection control measures. By offering a user-friendly, fast, and secure service, 1928 Diagnostics supports customers across healthcare, food, and environmental sectors in tracking and minimizing the spread of bacteria, viruses, and fungi on a global scale.

The idea for PictureMyLife born out of a personal experience and a need that They have seen are the others - to make life easier, more inspiring and stimulating for children with impaired comprehension skills as well as their families and educators. Today, much of the communication of children in handwritten contact books and schedules that put together the parts that must first be printed and then cut and pasted in place. They want to help change Their digital platform. They are founders and working with PictureMyLife named Yvonne Malmström Grimme, Lollo Andström, Lisa Lidgren and Maria Skantz and They have many years of experience in communication and education in health care, health and social care.

The PreciseInhale patented aerosol generation R&D platform delivers respirable dry powder aerosols from preclinical cell studies all the way through to human clinical trials, significantly accelerating drug development timelines. The platform’s one-animal-at-a-time system requires just milligrams, not grams of costly test substance for a full PK study and delivers high-resolution lung data of, typically, <10% SD. We carry out Contract Research for novel and generic inhalation drug developers, toxicology and environmental research institutes and university research institutes in the inhalation and aerosolization field.

Learning To Sleep offers clinically proven sleep improvement programs for people with sleep disorder through web and mobile devices. Their products has already helped over 40 000 people to live a better life and their unique business model establish also a strong relation between patients and their physicist.

Attana AB, founded in 2002 and based in Stockholm, Sweden, specializes in providing biologically relevant information that enhances the efficiency and performance of pharmaceutical drug development. The company develops third-generation analytical biosensor instruments that automate the analysis of molecular interactions with cells and tissues. These biosensors are utilized to determine binding characteristics, such as specificity, kinetics, and affinity of various biomolecules, including cells, antibodies, proteins, viruses, and bacteria. Attana serves a diverse clientele, including academic institutions, biotechnology firms, and pharmaceutical companies in Europe and Asia, and its technology has received validation from multiple reputable organizations in the field. The company also offers contract research services to further support the drug development process.